Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT02505009
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan
Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- SEARCH Research Foundation
- Target Recruit Count
- 15
- Registration Number
- NCT02475915
- Locations
- 🇹🇭
SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02452528
- Locations
- 🇺🇸
Kaiser Permanente, San Francisco, California, United States
🇺🇸Ichan School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Univ. Of Miami School Of Medicine/Center For Liver Diseases, Miami, Florida, United States
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02391805
- Locations
- 🇲🇾
University Malaya Medical Center, Kuala Lumpur, Malaysia
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Test Albuvirtide in Experienced Patients
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 418
- Registration Number
- NCT02369965
- Locations
- 🇨🇳
The Third People'S Hospital Of Shenzhen, Shenzhen, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Beijing Youan Hospital, Capital medical university, Beijing, Beijing, China
TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 121
- Registration Number
- NCT02338674
- Locations
- 🇨🇳
Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, China
The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02301650
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- Asian Institute Of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT02238860
- Locations
- 🇵🇰
Asian Institute of medical Sciences, Hyderabad, Sindh, Pakistan
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 6
- Registration Number
- NCT02039323
- Locations
- 🇺🇸
CTRC University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.